These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25787993)

  • 21. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
    Harding JJ; Lowery MA; Shih AH; Schvartzman JM; Hou S; Famulare C; Patel M; Roshal M; Do RK; Zehir A; You D; Selcuklu SD; Viale A; Tallman MS; Hyman DM; Reznik E; Finley LWS; Papaemmanuil E; Tosolini A; Frattini MG; MacBeth KJ; Liu G; Fan B; Choe S; Wu B; Janjigian YY; Mellinghoff IK; Diaz LA; Levine RL; Abou-Alfa GK; Stein EM; Intlekofer AM
    Cancer Discov; 2018 Dec; 8(12):1540-1547. PubMed ID: 30355724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
    Reitman ZJ; Yan H
    J Natl Cancer Inst; 2010 Jul; 102(13):932-41. PubMed ID: 20513808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
    Chen J; Yang J; Cao P
    Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1.
    Kim HJ; Choi BY; Keum YS
    J Cancer Prev; 2015 Mar; 20(1):78-83. PubMed ID: 25853107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
    Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
    Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
    Gu Y; Yang R; Yang Y; Zhao Y; Wakeham A; Li WY; Tseng A; Leca J; Berger T; Saunders M; Fortin J; Gao X; Yuan Y; Xiao L; Zhang F; Zhang L; Gao G; Zhou W; Wang Z; Mak TW; Ye J
    Blood; 2021 Feb; 137(7):945-958. PubMed ID: 33254233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
    Molenaar RJ; Wilmink JW
    J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
    Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
    Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic syndromes and malignant transformation: where the twain shall meet.
    Bhagwat N; Levine RL
    Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocitrate dehydrogenase mutations in leukemia.
    McKenney AS; Levine RL
    J Clin Invest; 2013 Sep; 123(9):3672-7. PubMed ID: 23999441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
    Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
    Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
    Jia P; Wu Y; Du H; Yang L; Zhang Z; Ma T; Li S; Yuan S; Lu L; Zha X
    Eur J Pharm Sci; 2019 Dec; 140():105072. PubMed ID: 31518680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.